Creative Planning Sells 55,044 Shares of Sanofi $SNY

Creative Planning decreased its stake in shares of Sanofi (NASDAQ:SNY) by 20.1% in the second quarter, Holdings Channel reports. The institutional investor owned 219,439 shares of the company’s stock after selling 55,044 shares during the quarter. Creative Planning’s holdings in Sanofi were worth $10,601,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Accent Capital Management LLC bought a new position in shares of Sanofi during the first quarter valued at $29,000. Eastern Bank grew its position in Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after purchasing an additional 300 shares during the last quarter. Ameritas Advisory Services LLC bought a new stake in Sanofi during the 2nd quarter valued at about $28,000. Banque Transatlantique SA bought a new stake in Sanofi during the 1st quarter valued at about $33,000. Finally, Brentview Investment Management LLC purchased a new position in Sanofi in the first quarter worth about $42,000. 14.03% of the stock is owned by institutional investors.

Sanofi Stock Down 2.2%

Shares of Sanofi stock opened at $50.66 on Wednesday. The company has a market cap of $124.40 billion, a price-to-earnings ratio of 11.86, a price-to-earnings-growth ratio of 1.38 and a beta of 0.49. The company’s 50 day moving average is $49.16 and its 200 day moving average is $49.35. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The company has a quick ratio of 0.94, a current ratio of 1.06 and a debt-to-equity ratio of 0.16.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 24th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.10. The business had revenue of $14.53 billion during the quarter, compared to the consensus estimate of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The firm’s revenue was down 7.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.25 EPS. Research analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on SNY. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research note on Tuesday, November 11th. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Sanofi currently has a consensus rating of “Buy” and an average price target of $62.67.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.